Skip to main content
Veterinary Medicines

Primun Newcastle C30 Lyophilisate for suspension

Authorised
  • Newcastle disease virus, strain NDV_CLS, Live

Product identification

Medicine name:
Primun Newcastle C30 Lyophilisate for suspension
Primun Newcastle C30 liofilizado para suspensão para galinhas
Active substance:
  • Newcastle disease virus, strain NDV_CLS, Live
Target species:
  • Chicken
Route of administration:
  • Oculonasal use

Product details

Active substance and strength:
  • Newcastle disease virus, strain NDV_CLS, Live
    6.00
    log 10 50% embryo infective dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate for suspension
Withdrawal period by route of administration:
  • Oculonasal use
    • Chicken
      • Meat and offal
        0
        day
      • Egg
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD06
Authorisation status:
  • Valid
Authorised in:
  • Portugal
Package description:
  • (ID1): 1 Box with 1 Bottle (Glass) with 1000 Dose (1000 Dose)
  • (ID3): 1 Box with 1 Bottle (Glass) with 2000 Dose (2000 Dose)
  • (ID2): 1 Box with 10 Bottle (Glass) with 1000 Dose (10000 Dose)
  • (ID4): 1 Box with 10 Bottle (Glass) with 2000 Dose (20000 Dose)

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Calier Portugal Medicamentos E Produtos Veterinarios S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Calier S.A.
Responsible authority:
  • Directorate General For Food And Veterinary
Authorisation number:
  • 956/01/18DIVPT
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0273/001
Concerned member states:
  • Italy
  • Poland
  • Portugal
  • Spain

Documents

Summary of Product Characteristics

English (PDF)
Published on: 28/01/2022
Download

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Portuguese (PDF)
Published on: 12/07/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."